NYSE
22.70USD
+0.51 (+2.30%)
We have scored 5 news catalysts on Alto Neuroscience, Inc. (ANRO) over the past 12 months. The biggest single-day move next to one of them came Nov 10, 2025, when ANRO closed +10.3%: “Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?”. Coverage across the window leans negative (average ticker sentiment −0.11). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
890.8M
P/E
—
EPS
—
Beta
1.16
52W range
10.2-37.48
Day range
22.33–23.14
Open
22.71
Prev close
22.19
Volume
505.2K
Avg volume
561.4K
Dividend
0.00
IPO
2024-02-02
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Alto Neuroscience, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ANRO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
